GO:0032746 positive regulation of interleukin-22 production: Immune Regulation, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0032746 describes any process that activates or increases the frequency, rate, or extent of interleukin-22 (IL-22) production.
• IL-22 is a cytokine mainly produced by innate lymphoid cells (ILC3), Th17 cells, and other immune cells, and it acts on epithelial cells to promote barrier defense and tissue repair.
• Microbiota-derived short-chain fatty acids (SCFAs) such as butyrate and acetate promote IL-22 production, linking diet and gut immunity.
• The aryl hydrocarbon receptor (AHR) pathway is a key driver of IL-22 production, and its modulation by tryptophan metabolites or interferon signaling affects IL-22 levels.
• Dysregulated IL-22 production is associated with inflammatory diseases including psoriasis, ulcerative colitis, and COVID-19.
• CRISPR-based models (knockout, knock-in, overexpression) enable causal dissection of genes regulating IL-22 production for therapeutic targeting.
Description
Interleukin-22 (IL-22) is a member of the IL-10 cytokine family that plays a central role in mucosal immunity and tissue regeneration. The Gene Ontology term GO:0032746, positive regulation of interleukin-22 production, encompasses all biological processes that activate or increase the frequency, rate, or extent of IL-22 production. This term is critical for understanding how the immune system coordinates barrier defense, as IL-22 acts primarily on non-hematopoietic cells such as epithelial cells to induce antimicrobial peptides and promote tissue repair. Researchers studying inflammatory bowel disease, psoriasis, and host-microbe interactions frequently focus on this process because IL-22 levels correlate with disease severity and mucosal healing. The regulation of IL-22 production is highly context-dependent, involving innate lymphoid cells (ILC3), Th17 cells, and other lymphocyte subsets. Key drivers include the aryl hydrocarbon receptor (AHR), which senses dietary and microbial metabolites, and cytokines such as IL-23 and IL-1β. Recent studies have highlighted the role of the gut microbiota and its metabolites, particularly short-chain fatty acids (SCFAs), in promoting IL-22 production and enhancing gut immunity. Understanding the positive regulation of IL-22 production at a molecular level is essential for developing targeted therapies that harness IL-22's protective functions without inducing pathology. This article synthesizes current knowledge on the mechanisms, genes, and research methods related to GO:0032746, providing a comprehensive resource for biomedical researchers.
positive regulation of interleukin-22 production At A Glance
| GO ID | GO:0032746 |
|---|---|
| GO term | positive regulation of interleukin-22 production |
| Ontology | biological_process |
| Synonym | activation of interleukin-22 production; positive regulation of IL-22 production; stimulation of interleukin-22 production; upregulation of interleukin-22 production |
| Major function | Enhances the production of IL-22, a cytokine critical for mucosal immunity and epithelial barrier function. |
| Related cytokines | IL-22, IL-23, IL-1β, IL-6 |
| Key cell types | Innate lymphoid cells (ILC3), Th17 cells, γδ T cells, NK cells |
| Upstream regulators | AHR, STAT3, RORγt, NF-κB |
| Associated diseases | Psoriasis, ulcerative colitis, COVID-19, inflammatory bowel disease |
What Is GO:0032746?
GO:0032746, positive regulation of interleukin-22 production, is defined as any process that activates or increases the frequency, rate, or extent of interleukin-22 production. This biological process includes signaling events, transcriptional activation, and cellular differentiation programs that lead to enhanced IL-22 synthesis and secretion. It is a child of the broader terms 'regulation of interleukin-22 production' and 'positive regulation of cytokine production'.
Why Is positive regulation of interleukin-22 production Important in Cell Biology?
The positive regulation of IL-22 production is a cornerstone of mucosal immunity and tissue homeostasis. IL-22 induces antimicrobial peptide production and epithelial regeneration, protecting against pathogens like Clostridioides difficile and maintaining gut barrier integrity. Dysregulation of this process contributes to chronic inflammatory diseases such as psoriasis and ulcerative colitis, where excessive IL-22 drives keratinocyte hyperproliferation or where insufficient IL-22 impairs barrier repair. Understanding the molecular players that enhance IL-22 production offers therapeutic opportunities to boost host defense or dampen inflammation. Moreover, the interplay between diet, microbiota, and IL-22 production highlights the importance of this GO term in precision nutrition and microbiome-based interventions.
• IL-22 enhances epithelial barrier function and antimicrobial defense in the gut and skin.
• SCFAs from dietary fiber promote IL-22 production, linking nutrition to immune health.
• AHR activation by tryptophan metabolites upregulates IL-22, offering a druggable pathway.
• IL-22 is protective in Clostridioides difficile infection by modulating MHC-II expression.
• Dysregulated IL-22 production is implicated in psoriasis pathogenesis.
• Interferon signaling can subvert AHR-JUN axis, altering IL-22 production in lupus.
• IL-22 levels are elevated in COVID-19 patients, suggesting a role in antiviral responses.
• OLFM4 modulates intestinal inflammation by promoting IL-22+ ILC3 cells.
• Cholesterol transport in T cells links dietary lipids to intestinal immune responses including IL-22.
• Targeting positive regulators of IL-22 production may treat inflammatory bowel diseases.
What Happens During positive regulation of interleukin-22 production?
Microbial and Dietary Metabolite Sensing
In simple terms: Gut microbes break down fiber into molecules that tell immune cells to make more IL-22.
Short-chain fatty acids (SCFAs) such as butyrate and acetate, produced by intestinal microbiota from dietary fiber, are potent inducers of IL-22 production. These metabolites act on immune cells, including ILC3 and T cells, to enhance IL-22 transcription and secretion. Acetate-mediated modulation of epithelial MHC-II expression also supports IL-22-dependent protection against Clostridioides difficile infection. This sensing mechanism links diet and microbiome composition directly to the positive regulation of IL-22 production.
Aryl Hydrocarbon Receptor (AHR) Activation
In simple terms: AHR acts like a sensor that, when triggered by certain dietary or microbial molecules, turns on IL-22 production.
The aryl hydrocarbon receptor (AHR) is a ligand-activated transcription factor that promotes IL-22 production in ILC3 and Th17 cells. Tryptophan metabolites derived from gut microbiota activate AHR, leading to increased IL-22 transcription. However, interferon signaling can subvert the AHR-JUN axis, altering the balance of T cell subsets and potentially reducing IL-22 production in autoimmune contexts like lupus. Thus, AHR is a central node in the positive regulation of IL-22 production.
Cytokine-Driven Signaling
In simple terms: Other immune messengers like IL-23 and IL-1β can boost IL-22 production.
Proinflammatory cytokines such as IL-23 and IL-1β synergize with AHR ligands to enhance IL-22 production in innate and adaptive lymphocytes. This cytokine-driven amplification is critical for rapid mucosal defense. Additionally, cholesterol transport in T cells has been shown to link intestinal immune responses to dietary lipid absorption, influencing IL-22 production. These signaling pathways converge on transcription factors like STAT3 and RORγt to upregulate IL-22 gene expression.
Cellular Sources and Differentiation
In simple terms: Different immune cell types, especially ILC3 and Th17 cells, are the main producers of IL-22.
IL-22 is primarily produced by group 3 innate lymphoid cells (ILC3), Th17 cells, γδ T cells, and NK cells. The positive regulation of IL-22 production involves the differentiation and activation of these cell populations. For example, OLFM4 promotes IL-22+ ILC3 in the gut, modulating intestinal inflammation. Autophagy-based unconventional secretion of HMGB1 by keratinocytes also contributes to psoriatic skin inflammation, where IL-22 plays a key role. Understanding the cellular sources is essential for targeting IL-22 production therapeutically.
Epigenetic and Transcriptional Control
In simple terms: Chemical tags on DNA and transcription factors control how much IL-22 is made.
Transcriptional regulation of the IL22 gene involves transcription factors such as AHR, RORγt, STAT3, and NF-κB. Epigenetic modifications, including histone acetylation and DNA methylation, can also influence IL-22 production. While specific epigenetic details are still emerging, the integration of these signals determines the magnitude and duration of IL-22 production. This layer of control ensures that IL-22 is produced appropriately in response to microbial and inflammatory cues.
Key Genes Involved in GO:0032746 positive regulation of interleukin-22 production
The following genes and proteins are key players in the positive regulation of interleukin-22 production, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| IL22 | Encodes the cytokine IL-22 | Target gene whose production is regulated; biomarker in inflammation |
| AHR | Ligand-activated transcription factor | Central driver of IL-22 production; druggable target |
| RORC | Transcription factor for Th17/ILC3 | Promotes IL-22 expression; knockout models reduce IL-22 |
| STAT3 | Signal transducer and transcription factor | Mediates cytokine-induced IL-22 production |
| IL23A | Subunit of IL-23 cytokine | Stimulates IL-22 production in ILC3 and Th17 cells |
| IL1B | Proinflammatory cytokine | Synergizes with IL-23 to enhance IL-22 |
| OLFM4 | Olfactomedin 4 | Promotes IL-22+ ILC3 in gut; modulates inflammation |
| HMGB1 | High mobility group box 1 | Autophagy-based secretion by keratinocytes in psoriasis |
| JUN | AP-1 transcription factor | Part of AHR-JUN axis; subverted by interferon |
| NR1H2 | Liver X receptor beta | Cholesterol transport links to intestinal immunity |
| NR1H3 | Liver X receptor alpha | Cholesterol transport links to intestinal immunity |
| MHC-II | Antigen presentation molecule | Modulated by acetate; affects C. difficile protection |
| GPR43 | SCFA receptor | Mediates SCFA-induced IL-22 production |
| GPR41 | SCFA receptor | Mediates SCFA-induced IL-22 production |
| IL17A | Cytokine co-expressed with IL-22 | Marker of Th17 cells; often co-regulated |
| IL6 | Proinflammatory cytokine | Induces IL-22 in combination with IL-23 |
| TGFB1 | Transforming growth factor beta | Modulates Th17 differentiation and IL-22 production |
How Is positive regulation of interleukin-22 production Regulated?
The positive regulation of IL-22 production is controlled at multiple levels. Extracellular signals include microbial metabolites (SCFAs), dietary components (tryptophan, cholesterol), and cytokines (IL-23, IL-1β, IL-6). These signals activate transcription factors such as AHR, RORγt, STAT3, and NF-κB, which bind to the IL22 promoter and enhancer regions. Interferon signaling can interfere with the AHR-JUN axis, reducing IL-22 production in autoimmune settings. Additionally, cholesterol transport pathways in T cells link dietary lipid absorption to intestinal immune responses, influencing IL-22 production. Post-transcriptional mechanisms, including mRNA stability and epigenetic modifications, further fine-tune IL-22 levels. This complex regulatory network ensures that IL-22 is produced appropriately in response to environmental and inflammatory cues.
positive regulation of interleukin-22 production and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| AHR | Ulcerative colitis, psoriasis | AHR knockout mice, AHR agonist treatment |
| IL22 | Psoriasis, IBD | IL-22 knockout mice, IL-22 overexpression |
| OLFM4 | Intestinal inflammation | OLFM4 knockout mice, ILC3-specific deletion |
| HMGB1 | Psoriasis | Keratinocyte-specific HMGB1 knockout |
| JUN | Lupus | JUN knockout T cells, interferon treatment |
Psoriasis
Psoriasis is a chronic inflammatory skin disease characterized by hyperproliferation of keratinocytes and increased IL-22 levels. Autophagy-based unconventional secretion of HMGB1 by keratinocytes plays a pivotal role in psoriatic skin inflammation, contributing to IL-22 production and Th17 responses. Targeting the positive regulation of IL-22 production may offer therapeutic benefits in psoriasis.
Ulcerative Colitis and Inflammatory Bowel Disease
In ulcerative colitis, impaired IL-22 production compromises intestinal barrier integrity. Gegen Qinlian decoction activates the AHR/IL-22 pathway to repair the intestinal barrier by modulating gut microbiota-related tryptophan metabolism. Similarly, OLFM4 promotes IL-22+ ILC3 to modulate intestinal inflammation, suggesting that enhancing IL-22 production could be protective.
COVID-19
Interleukin-22 and interleukin-33 show up-regulated levels in the serum of patients with mild/moderate Coronavirus disease 2019, indicating a potential role for IL-22 in antiviral defense and inflammation. Understanding the positive regulation of IL-22 production in this context may inform therapeutic strategies.
Lupus
Interferon subverts an AHR-JUN axis to promote CXCL13+ T cells in lupus, which may alter IL-22 production and contribute to autoimmunity. This highlights the importance of context-dependent regulation of IL-22 in autoimmune diseases.
From positive regulation of interleukin-22 production-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X regulate IL-22 production? | Knockout of gene X in mice or cell lines, measure IL-22 by ELISA/qPCR |
| Does a point mutation in gene X affect IL-22 production? | Point-mutation knock-in via CRISPR in cell lines or mice |
| Does overexpression of gene X enhance IL-22 production? | Overexpression cell lines or transgenic mice |
| Where is gene X expressed in IL-22-producing cells? | Tagged knock-in (e.g., GFP) for imaging and sorting |
| What is the transcriptional impact of gene X on IL22? | RNA-seq and ChIP-seq in knockout vs wild-type cells |
| Can CRISPR screening identify novel regulators of IL-22? | Genome-wide CRISPR library screening in IL-22 reporter cells |
How to Study the positive regulation of interleukin-22 production Process
| Method | What It Measures | Typical Application |
|---|---|---|
| ELISA | Secreted IL-22 protein | Quantify IL-22 in serum or culture supernatants |
| Flow cytometry | Intracellular IL-22 and cell surface markers | Identify IL-22+ cell subsets (ILC3, Th17) |
| RNA-seq | Global transcriptome including IL22 mRNA | Discover pathways regulating IL-22 production |
| CRISPR knockout | Loss-of-function of candidate genes | Test necessity of AHR, OLFM4, etc. |
| CRISPR knock-in | Tagged or mutant gene expression | Track IL-22-producing cells with reporters |
| 16S rRNA sequencing | Microbiota composition | Correlate microbial taxa with IL-22 levels |
| Metabolomics | SCFA and tryptophan metabolites | Link metabolites to IL-22 induction |
| ChIP-seq | Transcription factor binding at IL22 locus | Map AHR, STAT3 binding sites |
Quantifying IL-22 Production
IL-22 production is typically measured by ELISA, flow cytometry (intracellular cytokine staining), or ELISpot. These methods allow researchers to assess the frequency of IL-22+ cells and the amount of secreted cytokine in response to stimuli such as SCFAs or AHR ligands.
Transcriptional Analysis
RNA-seq and qPCR are used to measure IL22 mRNA levels and to identify global transcriptional changes in immune cells upon activation. Single-cell RNA-seq can resolve IL-22 production at the cellular level, identifying distinct subsets such as ILC3 and Th17 cells.
Genetic Perturbation with CRISPR
CRISPR-Cas9 knockout, knock-in, and overexpression models enable causal testing of candidate genes. For example, knocking out AHR or OLFM4 in cell lines or mice can reveal their necessity for IL-22 production. CRISPR screening can unbiasedly identify novel regulators.
Metabolite and Microbiota Studies
Germ-free or antibiotic-treated mice, fecal microbiota transplantation, and dietary interventions (e.g., fiber-rich diets) are used to study how microbial metabolites like SCFAs influence IL-22 production. Metabolomics can quantify SCFA levels in gut contents.
How CRISPR Can Be Used to Study GO:0032746 positive regulation of interleukin-22 production
Knockout
CRISPR knockout of candidate genes such as AHR, OLFM4, or HMGB1 in cell lines or mice allows researchers to determine whether these genes are required for IL-22 production. For example, AHR knockout reduces IL-22 levels and impairs barrier function. OLFM4 knockout decreases IL-22+ ILC3 and exacerbates intestinal inflammation.
Point Mutation
Point mutations can be introduced into genes like STAT3 or AHR to mimic human variants or to dissect specific phosphorylation sites. These models help determine how subtle genetic changes affect IL-22 production and downstream immunity.
Knock-in
Knock-in of reporter genes (e.g., GFP) into the IL22 locus enables real-time tracking of IL-22-producing cells. Tagged knock-in of AHR or other regulators allows visualization of protein localization and interaction dynamics in live cells.
Overexpression
Overexpression of candidate genes such as IL23A or AHR in cell lines or transgenic mice can test sufficiency for enhancing IL-22 production. This approach is useful for validating therapeutic targets that boost IL-22-mediated barrier protection.
How EDITGENE Supports positive regulation of interleukin-22 production Research
Researchers studying positive regulation of interleukin-22 production-related genes often need to determine whether a candidate gene is causally involved in IL-22 regulation or merely correlated with it. CRISPR-based models provide the gold standard for establishing causality, enabling precise genetic perturbations in relevant immune cell types.
Contact EDITGENE today to design your custom CRISPR model for positive regulation of interleukin-22 production research.
Frequently Asked Questions About positive regulation of interleukin-22 production
What is GO:0032746?
GO:0032746 is the Gene Ontology term for positive regulation of interleukin-22 production, describing any process that activates or increases the frequency, rate, or extent of IL-22 production.
What genes are involved in positive regulation of interleukin-22 production?
Key genes include AHR, RORC, STAT3, IL23A, IL1B, OLFM4, and HMGB1, among others.
How is IL-22 production regulated?
IL-22 production is regulated by microbial metabolites (SCFAs), dietary components, cytokines (IL-23, IL-1β), and transcription factors such as AHR and RORγt.
What diseases are associated with IL-22 production?
Diseases include psoriasis, ulcerative colitis, COVID-19, and lupus, where IL-22 levels are dysregulated.
Which cells produce IL-22?
IL-22 is primarily produced by innate lymphoid cells (ILC3), Th17 cells, γδ T cells, and NK cells.
How can I study positive regulation of IL-22 production?
Common methods include ELISA, flow cytometry, RNA-seq, and CRISPR knockout/knock-in models.
What is the role of AHR in IL-22 production?
AHR is a ligand-activated transcription factor that promotes IL-22 production upon binding to tryptophan metabolites.
Do short-chain fatty acids increase IL-22?
Yes, SCFAs such as butyrate and acetate promote IL-22 production and enhance gut immunity.
Can CRISPR be used to study IL-22 regulation?
Yes, CRISPR knockout, knock-in, and overexpression models are powerful tools to dissect genes regulating IL-22 production.
What is the clinical significance of IL-22?
IL-22 is critical for mucosal immunity and tissue repair; targeting its production may treat inflammatory diseases.
Conclusion
The positive regulation of interleukin-22 production (GO:0032746) is a vital biological process that bridges diet, microbiota, and immune defense. Key regulators such as AHR, SCFAs, and cytokines orchestrate IL-22 production to maintain barrier integrity and protect against pathogens. Dysregulation of this process contributes to inflammatory diseases including psoriasis, ulcerative colitis, and COVID-19. Advances in CRISPR-based models and multi-omics approaches are accelerating the discovery of novel regulators and therapeutic targets. EDITGENE's comprehensive services empower researchers to dissect this pathway with precision and translate findings into clinical applications.
References
- 1. Yang W et al.. 2020. Intestinal microbiota-derived short-chain fatty acids regulation of immune cell IL-22 production and gut immunity.. Nat Commun 11(1):4457 PMID: 32901017
- 2. Law C et al.. 2024. Interferon subverts an AHR-JUN axis to promote CXCL13(+) T cells in lupus.. Nature 631(8022):857-866 PMID: 38987586
- 3. Wang Z et al.. 2021. Autophagy-based unconventional secretion of HMGB1 by keratinocytes plays a pivotal role in psoriatic skin inflammation.. Autophagy 17(2):529-552 PMID: 32019420
- 4. Gao Y et al.. 2025. T cell cholesterol transport links intestinal immune responses to dietary lipid absorption.. Science 390(6769):eadt4169 PMID: 41066556
- 5. Fachi JL et al.. 2025. Fiber- and acetate-mediated modulation of MHC-II expression on intestinal epithelium protects from Clostridioides difficile infection.. Cell Host Microbe 33(2):235-251.e7 PMID: 39826540
- 6. Wang X et al.. 2023. Gegen Qinlian decoction activates AhR/IL-22 to repair intestinal barrier by modulating gut microbiota-related tryptophan metabolism in ulcerative colitis mice.. J Ethnopharmacol 302(Pt B):115919 PMID: 36356716
- 7. Xing Z et al.. 2024. OLFM4 modulates intestinal inflammation by promoting IL-22(+)ILC3 in the gut.. Commun Biol 7(1):914 PMID: 39075283
- 8. Majeed AY et al.. 2023. Interleukin-22 and interleukin-33 show up-regulated levels in the serum of patients with mild/moderate Coronavirus disease 2019.. Beni Suef Univ J Basic Appl Sci 12(1):24 PMID: 36875710
